FDA grants Genentech priority review for recurrent platinum-resistant ovarian cancer
Genentech announced that the FDA has accepted the company's supplemental Biologics License Application and granted Priority Review for Avastin® (bevacizumab) plus chemotherapy for the treatment of women with recurrent platinum-resistant ovarian cancer. July 22, 2014